Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race

Pfizer has seven immuno-oncology drugs in the clinic and an ambition to be the first drug maker to bring a PD-1/OX40/4-1BB triplet regimen into the clinic late this year or early next.